Media Articles Related to Vinorelbine
ALK-positive non-small cell lung cancer: significant discrepancies between FISH and IHC results for ALK testing
Source: Lung Cancer News From Medical News Today [2014.02.26]
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor.
Added benefit of Afatinib depends on mutation status in non-small cell lung cancer
Source: Lung Cancer News From Medical News Today [2014.02.21]
Lung cancer patients with Del19 mutation benefit mostAfatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
Radiation and chemotherapies could be more effective in treating the most common and deadly of all cancers by eliminating Mcl-1
Source: Health News from Medical News Today [2014.03.07]
Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer, which by far kills more patients than any other type of cancer; accounting for more than 1 in 4 cancer deaths in the U.S. annually. The 5-year survival rate for advanced NSCLC is less than 10 percent.
Preop PET Cuts Lung Cancer Surgery
Source: MedPageToday.com - medical news plus CME for physicians [2014.03.07]
(MedPage Today) -- Routine preoperative PET imaging led to a significant reduction in unnecessary surgery for non-small cell lung cancer, a review of almost 1,000 cases showed.
OncoBriefs: Lung Trial Ended, Gene Test Helpful
Source: MedPage Today Gastroenterology [2014.03.04]
(MedPage Today) -- The addition of one targeted agent to another did not improve survival in non-small cell lung cancer, and a genetic test for prostate cancer affected patients' treatment plans, two new studies showed.
Published Studies Related to Vinorelbine
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study. [2011.05]
BACKGROUND/PURPOSE: This study compared front-line treatment with docetaxel or vinorelbine in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Docetaxel has an efficacy comparable to that of vinorelbine as first-line treatment in elderly patients with NSCLC and has an acceptable toxicity profile. The trial was closed prematurely because of low accrual, thus limiting the strength of the conclusions derived. Copyright (c) 2011. Published by Elsevier Inc.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). [2011.04]
BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer... CONCLUSION: Although response rate, PFS and survival were non-different in both groups, toxicity was significantly worse in group B and therefore further investigation of P-Vin is of no value. (c) The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. [2011.03.29]
BACKGROUND: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory... CONCLUSIONS: This randomised phase II trial has revealed comparable results for three gemcitabine-based regimens regarding treatment efficacy and toxicity. Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated patients with metastatic breast cancer.
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. [2011.03]
PURPOSE: This study evaluates the activity and toxicity of the paclitaxel/carboplatin (PC) doublet versus vinorelbine/carboplatin (VC) doublet as second-line treatment in patients who have advanced non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Platinum-based doublets with either paclitaxel or vinorelbine in patients with advanced/metastatic NSCLC pretreated with front-line docetaxel/gemcitabine show comparable efficacy when used in the second-line setting. Copyright (c) 2011. Published by Elsevier Inc.
Clinical Trials Related to Vinorelbine
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer [Completed]
The purpose of this study is it to determine how well patients with non-small cell lung
cancer respond to cetuximab plus vinorelbine. We would also like to determine the safety of
cetuximab plus vinorelbine in people 70 years of age or older with advanced non-small cell
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer [Completed]
The purpose of this study is to compare two different combinations of chemotherapy with
trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the
patients will receive trastuzumab in combination with a taxane form of chemotherapy (either
paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with
Vinorelbine/Gemcitabine Verses Vinorelbine/Carboplatin in Advanced Non-Small Cell Lung Cancer [Recruiting]
BIBW 2992 and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2 [Recruiting]
To identify the MTD of BIBW 2992 therapy in combination with vinorelbine i. v. and oral
Safety and anti-tumour efficacy data and determination of pharmacokinetic characteristics of
BIBW 2992, vinorelbine i. v. and vinorelbine oral.
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects [Recruiting]
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of
vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2
overexpressing metastatic breast cancer (MBC). Sixty subjects will be enrolled in the
study. Subjects will receive vinorelbine intravenously once weekly for 3 weeks, followed by
a rest week in a 4-week cycle) plus lapatinib daily. Subjects will receive treatment until
disease progression or withdrawal from the study. The primary objective of this study is to
evaluate overall tumor response rate of lapatinib in combination with vinorelbine.
Secondary objectives include progression-free survival, overall survival, duration of
response, time to response and time to progression and safety. Safety and efficacy
assessments will be performed at 4, 8 and 12 week intervals, and at the end of treatment.
Subject: Metastatic Breast Cancer, ErbB2, First-line or Second-line therapy, Lapatinib,
Reports of Suspected Vinorelbine Side Effects
Hepatic Failure (22),
Neutropenic Sepsis (21),
Febrile Neutropenia (20),
Interstitial Lung Disease (15),
Constipation (11), more >>